Merl Man Yee, Abdelghany Osama, Li Jia, Saif Muhammad Wasif
Yale-New Haven Hospital, New Haven, CT, USA.
JOP. 2010 Jul 5;11(4):317-20.
Pancreatic cancer is one of the most devastating solid tumor malignancies. Majority of patients have metastatic disease upon diagnosis. Five-year survival is less than 5% for all stages of pancreatic cancer combined. Gemcitabine has been the standard palliative therapy for advanced pancreatic cancer over the past decade. Many studies attempted to develop combination regimens, but they failed to improve overall survival in the metastatic settings. The combination of gemcitabine and erlotinib was the first combination regimen to show improvements in survival benefit compared with gemcitabine alone and became the first-line combination therapy in advanced pancreatic cancer. The search for better treatment strategies to prolong survival in this deadly disease is very much needed and is a worldwide effort. There were many studies presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting focused on first-line therapy in metastatic pancreatic cancer. This article highlights a few phase III and II studies that have demonstrated encouraging results.
胰腺癌是最具毁灭性的实体瘤恶性肿瘤之一。大多数患者在确诊时已发生转移。所有阶段胰腺癌综合起来的五年生存率不到5%。在过去十年中，吉西他滨一直是晚期胰腺癌的标准姑息治疗药物。许多研究试图开发联合治疗方案，但在转移性情况下未能提高总生存率。吉西他滨与厄洛替尼联合使用是首个显示出与单用吉西他滨相比生存获益有所改善的联合治疗方案，并成为晚期胰腺癌的一线联合治疗方法。迫切需要寻找更好的治疗策略来延长这种致命疾病患者的生存期，这是一项全球性的努力。在2010年美国临床肿瘤学会（ASCO）年会上有许多关于转移性胰腺癌一线治疗的研究报告。本文重点介绍了一些已显示出令人鼓舞结果的III期和II期研究。
